Anthony Howell, Howell A, Howell T

List of Publications by Year
in descending order

307 papers	28,675 citations	2975 93 h-index	5829 161 g-index
314 all docs	314 docs citations	314 times ranked	27716 citing authors

#	Article	IF	Citations
1	The impact of China's R&D subsidies on R&D investment, technological upgrading and economic growth. Technological Forecasting and Social Change, 2022, 174, 121212.	11.6	75
2	Rare germline copy number variants (CNVs) and breast cancer risk. Communications Biology, 2022, 5, 65.	4.4	6
3	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
4	Breast cancer risks associated with missense variants in breast cancer susceptibility genes. Genome Medicine, 2022, 14, 51.	8.2	19
5	Socio-economic impacts of scaling back a massive payments for ecosystem services programme in China. Nature Human Behaviour, 2022, 6, 1218-1225.	12.0	8
6	Combined Associations of a Polygenic Risk Score and Classical Risk Factors With Breast Cancer Risk. Journal of the National Cancer Institute, 2021, 113, 329-337.	6.3	45
7	Breast Cancer Risk Genes â€" Association Analysis in More than 113,000 Women. New England Journal of Medicine, 2021, 384, 428-439.	27.0	532
8	Association of germline genetic variants with breast cancer-specific survival in patient subgroups defined by clinic-pathological variables related to tumor biology and type of systemic treatment. Breast Cancer Research, 2021, 23, 86.	5.0	7
9	Agglomeration, absorptive capacity and knowledge governance: implications for publicâ€"private firm innovation in China. Regional Studies, 2020, 54, 1069-1083.	4.4	35
10	Minimum wage impacts on Han-minority Workersâ€™ wage distribution and inequality in urban china. Journal of Urban Economics, 2020, 115, 103184.	4.4	15
11	Industry relatedness, FDI liberalization and the indigenous innovation process in China. Regional Studies, 2020, 54, 229-243.	4.4	39
12	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. Nature Genetics, 2020, 52, 56-73.	21.4	120
13	Picking 'winners' in space: Impact of spatial targeting on firm performance in China. Journal of Regional Science, 2020, 60, 1025-1046.	3.3	5
14	Explaining the urban premium in Chinese cities and the role of place-based policies. Environment and Planning A, 2020, 52, 1332-1356.	3.6	6
15	Going out to innovate more at home: Impacts of outward direct investments on Chinese firms' domestic innovation performance. China Economic Review, 2020, 60, 101404.	4.4	19
16	A network analysis to identify mediators of germline-driven differences in breast cancer prognosis. Nature Communications, 2020, 11, 312.	12.8	30
17	Reply to Comment on â€œThe effectiveness of home versus community-based weight control programmes initiated soon after breast cancer diagnosis: a randomised controlled trialâ€• British Journal of Cancer, 2020, 122, 925-926.	6.4	0
18	Heterogeneous impacts of China's economic and development zone program. Journal of Regional Science, 2019, 59, 797-818.	3.3	27

#	Article	IF	Citations
19	Relatedness economies, absorptive capacity, and economic catch-up: firm-level evidence from China. Industrial and Corporate Change, 2019, , .	2.8	1
20	Clustering effects on firm exporting with productivityâ€enhancing R&D in China. World Economy, 2019, 42, 3168-3187.	2.5	2
21	Genome-wide association study of germline variants and breast cancer-specific mortality. British Journal of Cancer, 2019, 120, 647-657.	6.4	52
22	Ethnic entrepreneurship, initial financing, and business performance in China. Small Business Economics, 2019, 52, 697-712.	6.7	49
23	Intermittent energy restriction for weight loss: Spontaneous reduction of energy intake on unrestricted days. Food Science and Nutrition, 2018, 6, 674-680.	3.4	18
24	Penetrance estimates for BRCA1, BRCA2 (also applied to Lynch syndrome) based on presymptomatic testing: a new unbiased method to assess risk?. Journal of Medical Genetics, 2018, 55, 442-448.	3.2	1
25	Use of Single-Nucleotide Polymorphisms and Mammographic Density Plus Classic Risk Factors for Breast Cancer Risk Prediction. JAMA Oncology, 2018, 4, 476.	7.1	109
26	Psychosocial issues of a population approach to high genetic risk identification: Behavioural, emotional and informed choice issues. Breast, 2018, 37, 148-153.	2.2	17
27	Personalized prevention in high risk individuals: Managing hormones and beyond. Breast, 2018, 39, 139-147.	2.2	18
28	Agglomeration, (un)â€related variety and new firm survival in China: Do local subsidies matter?. Papers in Regional Science, 2018, 97, 485-501.	1.9	52
29	Recruitment to the â€œBreastâ€”Activity and Healthy Eating After Diagnosisâ€•(B-AHEAD) Randomized Controlled Trial. Integrative Cancer Therapies, 2018, 17, 131-137.	2.0	9
30	RAZOR: A Phase II Open Randomized Trial of Screening Plus Goserelin and Raloxifene Versus Screening Alone in Premenopausal Women at Increased Risk of Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 58-66.	2.5	3
31	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. Annals of Internal Medicine, 2018, 168, 326.	3.9	37
32	Breast cancer risk in a screening cohort of Asian and white British/Irish women from Manchester UK. BMC Public Health, 2018, 18, 178.	2.9	18
33	Psychological impact of providing women with personalised 10-year breast cancer risk estimates. British Journal of Cancer, 2018, 118, 1648-1657.	6.4	41
34	Reader performance in visual assessment of breast density using visual analogue scales: are some readers more predictive of breast cancer?. , 2018, , .		0
35	Impact of a Panel of 88 Single Nucleotide Polymorphisms on the Risk of Breast Cancer in High-Risk Women: Results From Two Randomized Tamoxifen Prevention Trials. Journal of Clinical Oncology, 2017, 35, 743-750.	1.6	58
36	The impact of using weight estimated from mammographic images vs. self-reported weight on breast cancer risk calculation. Proceedings of SPIE, 2017, 10134, .	0.8	0

#	Article	IF	Citations
37	The impact of a panel of 18 SNPs on breast cancer risk in women attending a UK familial screening clinic: a caseâ€“control study. Journal of Medical Genetics, 2017, 54, 111-113.	3.2	56
38	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. World Development, 2017, 94, 200-211.	4.9	73
39	Picking â€˜winners' in China: Do subsidies matter for indigenous innovation and firm productivity?. China Economic Review, 2017, 44, 154-165.	4.4	110
40	Does the prediction of breast cancer improve using a combination of mammographic density measures compared to individual measures alone?. Proceedings of SPIE, 2017, , .	0.8	0
41	Visual assessment of breast density using Visual Analogue Scales: observer variability, reader attributes and reading time. , 2017, , .		3
42	Marshallian Sources of Relatedness and Their Effects on Firm Survival and Subsequent Success in China. Economic Geography, 2017, 93, 346-366.	4.6	19
43	A randomised trial of screening with digital breast tomosynthesis plus conventional digital 2D mammography versus 2D mammography alone in younger higher risk women. European Journal of Radiology, 2017, 94, 133-139.	2.6	8
44	Identifying the Sources of Agglomeration Benefits within China's Economic and Development Zones. SSRN Electronic Journal, 2017, , .	0.4	1
45	Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I). Journal of Clinical Oncology, 2017, 35, 2666-2673.	1.6	40
46	Do Marshallian Sources Drive Technological Relatedness? Implications for Firm Survival And Subsequent Success in China. SSRN Electronic Journal, 2016, , .	0.4	4
47	Impacts of Migration and Remittances on Ethnic Income Inequality in Rural China. SSRN Electronic Journal, 2016, , .	0.4	1
48	Marshallian Sources of Relatedness, Technological Capabilities and Firm Productivity in China. SSRN Electronic Journal, 2016, , .	0.4	5
49	How to Manage the Obese Patient With Cancer. Journal of Clinical Oncology, 2016, 34, 4284-4294.	1.6	45
50	Breast cancer risk feedback to women in the UK NHS breast screening population. British Journal of Cancer, 2016, 114, 1045-1052.	6.4	73
51	Relationship of ZNF423 and CTSO with breast cancer risk in two randomised tamoxifen prevention trials. Breast Cancer Research and Treatment, 2016, 158, 591-596.	2.5	5
52	Firm R&D, innovation and easing financial constraints in China: Does corporate tax reform matter?. Research Policy, 2016, 45, 1996-2007.	6.4	159
53	Intermittent energy restriction induces changes in breast gene expression and systemic metabolism. Breast Cancer Research, 2016, 18, 57.	5.0	37
54	Anastrozole versus tamoxifen for the prevention of locoregional and contralateral breast cancer in postmenopausal women with locally excised ductal carcinoma in situ (IBIS-II DCIS): a double-blind, randomised controlled trial. Lancet, The, 2016, 387, 866-873.	13.7	149

#	Article	IF	Citations
55	No strong evidence for increased risk of breast cancer 8â€“26 years after multiple mammograms in their 30s in females at moderate and high familial risk. British Journal of Radiology, 2016, 89, 20150960.	2.2	2
56	Anastrozole-Induced Carpal Tunnel Syndrome: Results From the International Breast Cancer Intervention Study II Prevention Trial. Journal of Clinical Oncology, 2016, 34, 139-143.	1.6	30
57	Mammographic Density Over Time in Women With and Without Breast Cancer. Lecture Notes in Computer Science, 2016, , 291-298.	1.3	1
58	Challenges and Opportunities in the Implementation of Risk-Based Screening for Breast Cancer. , 2016, , 165-187.		0
59	Should We Adjust Visually Assessed Mammographic Density for Observer Variability?. Lecture Notes in Computer Science, 2016, , 540-547.	1.3	0
60	Variations in Breast Density and Mammographic Risk Factors in Different Ethnic Groups. Lecture Notes in Computer Science, 2016, , 510-517.	1.3	0
61	Can the breast screening appointment be used to provide risk assessment and prevention advice?. Breast Cancer Research, 2015, 17, 84.	5.0	30
62	Mammographic density adds accuracy to both the Tyrer-Cuzick and Gail breast cancer risk models in a prospective UK screening cohort. Breast Cancer Research, 2015, 17, 147.	5.0	186
63	Longer term effects of the Angelina Jolie effect: increased risk-reducing mastectomy rates in BRCA carriers and other high-risk women. Breast Cancer Research, 2015, 17, 143.	5.0	77
64	Antibiotics that target mitochondria effectively eradicate cancer stem cells, across multiple tumor types: Treating cancer like an infectious disease. Oncotarget, 2015, 6, 4569-4584.	1.8	401
65	Can Diet and Lifestyle Prevent Breast Cancer: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e66-e73.	3.8	75
66	Tumour characteristics and survival in familial breast cancer prospectively diagnosed by annual mammography. Breast Cancer Research and Treatment, 2015, 152, 87-94.	2.5	2
67	Local mammographic density as a predictor of breast cancer. Proceedings of SPIE, 2015, , .	0.8	2
68	Estrogen Receptor Expression in 21-Gene Recurrence Score Predicts Increased Late Recurrence for Estrogen-Positive/HER2-Negative Breast Cancer. Clinical Cancer Research, 2015, 21, 2763-2770.	7.0	36
69	Tamoxifen for prevention of breast cancer: extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncology, The, 2015, 16, 67-75.	10.7	349
70	Beliefs about weight and breast cancer: an interview study with high risk women following a 12Âmonth weight loss intervention. Hereditary Cancer in Clinical Practice, 2015, 13, 1.	1.5	25
71	Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity. Cell Reports, 2015, 12, 1968-1977.	6.4	164
72	â€˜Indigenousâ€™ innovation with heterogeneous risk and new firm survival in a transitioning Chinese economy. Research Policy, 2015, 44, 1866-1876.	6.4	58

#	Article	IF	Citations
73	Targeting tumor-initiating cells: Eliminating anabolic cancer stem cells with inhibitors of protein synthesis or by mimicking caloric restriction. Oncotarget, 2015, 6, 4585-4601.	1.8	55
74	Epithelial and Stromal MicroRNA Signatures of Columnar Cell Hyperplasia Linking Let-7c to Precancerous and Cancerous Breast Cancer Cell Proliferation. PLoS ONE, 2014, 9, e105099.	2.5	21
75	JNK1 stress signaling is hyper-activated in high breast density and the tumor stroma: Connecting fibrosis, inflammation, and stemness for cancer prevention. Cell Cycle, 2014, 13, 580-599.	2.6	52
76	Can multiple SNP testing in BRCA2 and BRCA1 female carriers be used to improve risk prediction models in conjunction with clinical assessment?. BMC Medical Informatics and Decision Making, 2014, 14, 87.	3.0	9
77	Mammographic breast density refines Tyrer-Cuzick estimates of breast cancer risk in high-risk women: findings from the placebo arm of the International Breast Cancer Intervention Study I. Breast Cancer Research, 2014, 16, 451.	5.0	74
78	Changes in bone mineral density at 3 years in postmenopausal women receiving anastrozole and risedronate in the IBIS-II bone substudy: an international, double-blind, randomised, placebo-controlled trial. Lancet Oncology, The, 2014, 15, 1460-1468.	10.7	56
79	Breast Cancer Risk in Young Women in the National Breast Screening Programme: Implications for Applying NICE Guidelines for Additional Screening and Chemoprevention. Cancer Prevention Research, 2014, 7, 993-1001.	1.5	37
80	Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): an international, double-blind, randomised placebo-controlled trial. Lancet, The, 2014, 383, 1041-1048.	13.7	504
81	Breast cancer risk assessment in 8,824 women attending a family history evaluation and screening programme. Familial Cancer, 2014, 13, 189-196.	1.9	22
82	Long-term prospective clinical follow-up afterBRCA1/2presymptomatic testing:BRCA2risks higher than in adjusted retrospective studies. Journal of Medical Genetics, 2014, 51, 573-580.	3.2	15
83	Risk determination and prevention of breast cancer. Breast Cancer Research, 2014, 16, 446.	5.0	248
84	The Angelina Jolie effect: how high celebrity profile can have a major impact on provision of cancer related services. Breast Cancer Research, 2014, 16, 442.	5.0	252
85	Use of Volumetric Breast Density Measures for the Prediction of Weight and Body Mass Index. Lecture Notes in Computer Science, 2014, , 282-289.	1.3	2
86	Contralateral breast cancer risk in BRCA1/2-positive families needs to be adjusted for phenocopy rates particularly in second-degree untested relatives. Breast Cancer Research, 2013, 15, 401.	5.0	1
87	Contralateral mastectomy improves survival in women with BRCA1/2-associated breast cancer. Breast Cancer Research and Treatment, 2013, 140, 135-142.	2.5	144
88	Critical research gaps and translational priorities for the successful prevention and treatment of breast cancer. Breast Cancer Research, 2013, 15, R92.	5.0	320
89	Risk-reducing surgery increases survival in BRCA1/2 mutation carriers unaffected at time of family referral. Breast Cancer Research and Treatment, 2013, 142, 611-618.	2.5	58
90	The effect of intermittent energy and carbohydrate restrictionv. daily energy restriction on weight loss and metabolic disease risk markers in overweight women. British Journal of Nutrition, 2013, 110, 1534-1547.	2.3	336

#	Article	IF	Citations
91	Reverse Warburg Effect in a Patient With Aggressive B-Cell Lymphoma: Is Lactic Acidosis a Paraneoplastic Syndrome?. Seminars in Oncology, 2013, 40, 403-418.	2.2	40
92	Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncology, The, 2013, 14, 989-998.	10.7	246
93	Breast cancer prevention: SERMs come of age. Lancet, The, 2013, 381, 1795-1797.	13.7	6
94	Creating a tumor-resistant microenvironment: Cell-mediated delivery of TNFÎ± completely prevents breast cancer tumor formation in vivo. Cell Cycle, 2013, 12, 480-490.	2.6	26
95	Increased Rate of Phenocopies in All Age Groups in BRCA1/BRCA2 Mutation Kindred, but Increased Prospective Breast Cancer Risk Is Confined to BRCA2 Mutation Carriers. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 2269-2276.	2.5	13
96	Cigarette smoke metabolically promotes cancer, via autophagy and premature aging in the host stromal microenvironment. Cell Cycle, 2013, 12, 818-825.	2.6	51
97	Ovarian cancer among 8005 women from a breast cancer family history clinic: no increased risk of invasive ovarian cancer in families testing negative forBRCA1andBRCA2. Journal of Medical Genetics, 2013, 50, 368-372.	3.2	23
98	Ethanol exposure induces the cancer-associated fibroblast phenotype and lethal tumor metabolism. Cell Cycle, 2013, 12, 289-301.	2.6	43
99	Carbonic anhydrase 9 (CA9) and redox signaling in cancer-associated fibroblasts: Therapeutic implications. Cell Cycle, 2013, 12, 2534-2534.	2.6	3
100	Stromal glycolysis and MCT4 are hallmarks of DCIS progression to invasive breast cancer. Cell Cycle, 2013, 12, 2935-2936.	2.6	11
101	Oncogenes and inflammation rewire host energy metabolism in the tumor microenvironment. Cell Cycle, 2013, 12, 2580-2597.	2.6	75
102	Mitochondrial dysfunction in breast cancer cells prevents tumor growth. Cell Cycle, 2013, 12, 172-182.	2.6	76
103	Same task, same observers, different values: the problem with visual assessment of breast density. , 2013, , .		4
104	CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, â€œfuelingâ€•tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle, 2012, 11, 3599-3610.	2.6	182
105	Are We Ready for Online Tools in Decision Making for BRCA1/2 Mutation Carriers?. Journal of Clinical Oncology, 2012, 30, 471-473.	1.6	9
106	Detection and management of women at increased risk of breast cancer. Clinical Practice (London,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	0.1	0
107	Ketone body utilization drives tumor growth and metastasis. Cell Cycle, 2012, 11, 3964-3971.	2.6	152
108	Metabolic reprogramming and two-compartment tumor metabolism. Cell Cycle, 2012, 11, 3280-3289.	2.6	77

#	Article	IF	Citations
109	Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. Cell Cycle, 2012, 11, 3403-3414.	2.6	42
110	Two-compartment tumor metabolism: Autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle, 2012, 11, 2545-2559.	2.6	107
111	CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle, 2012, 11, 2272-2284.	2.6	116
112	BRCA1 mutations drive oxidative stress and glycolysis in the tumor microenvironment. Cell Cycle, 2012, 11, 4402-4413.	2.6	71
113	Breast Cancer Risk for Noncarriers of Family-Specific BRCA1 and BRCA2 Mutations: More Trouble With Phenocopies. Journal of Clinical Oncology, 2012, 30, 1142-1143.	1.6	5
114	Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle, 2012, 11, 253-263.	2.6	57
115	Genesis and Outcome of a Breast Cancer Trial to Develop the Aromatase Inhibitor Anastrozole. Clinical Chemistry, 2012, 58, 782-783.	3.2	1
116	Hereditary ovarian cancer and two-compartment tumor metabolism. Cell Cycle, 2012, 11, 4152-4166.	2.6	53
117	Mitochondria â€œfuelâ€•breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells. Cell Cycle, 2012, 11, 4390-4401.	2.6	147
118	Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle, 2012, 11, 3956-3963.	2.6	103
119	Warburg Meets Autophagy: Cancer-Associated Fibroblasts Accelerate Tumor Growth and MetastasisviaOxidative Stress, Mitophagy, and Aerobic Glycolysis. Antioxidants and Redox Signaling, 2012, 16, 1264-1284.	5.4	254
120	Oestrogen and breast cancer: results from the WHI trial. Lancet Oncology, The, 2012, 13, 437-438.	10.7	74
121	Effects of cyclin D1 gene amplification and protein expression on time to recurrence in postmenopausal breast cancer patients treated with anastrozole or tamoxifen: a TransATAC study. Breast Cancer Research, 2012, 14, R57.	5.0	75
122	Assessing Individual Breast Cancer Risk within the U.K. National Health Service Breast Screening Program: A New Paradigm for Cancer Prevention. Cancer Prevention Research, 2012, 5, 943-951.	1.5	104
123	Metabolic reprogramming of cancer-associated fibroblasts by TGF-Î² drives tumor growth: Connecting TGF-Î² signaling with â€œWarburg-likeâ€•cancer metabolism and L-lactate production. Cell Cycle, 2012, 11, 3019-3035.	2.6	249
124	Endometrial cancer and venous thromboembolism in women under age 50 who take tamoxifen for prevention of breast cancer: A systematic review. Cancer Treatment Reviews, 2012, 38, 318-328.	7.7	77
125	Energy restriction and the prevention of breast cancer. Proceedings of the Nutrition Society, 2012, 71, 263-275.	1.0	33
126	The milk protein Î±-casein functions as a tumor suppressor via activation of STAT1 signaling, effectively preventing breast cancer tumor growth and metastasis. Cell Cycle, 2012, 11, 3972-3982.	2.6	31

#	Article	IF	Citations
127	Mitochondrial metabolism in cancer metastasis. Cell Cycle, 2012, 11, 1445-1454.	2.6	162
128	Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle, 2012, 11, 4174-4180.	2.6	105
129	Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1Î±, autophagy and ketone body production. Cell Cycle, 2012, 11, 4167-4173.	2.6	40
130	Surveillance of women at increased risk of breast cancer using mammography and clinical breast examination: Further evidence of benefit. International Journal of Cancer, 2012, 131, 417-425.	5.1	23
131	Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis, via glycolysis and ketone production. Cell Cycle, 2012, 11, 2285-2302.	2.6	209
132	Caveolin-1 and Cancer Metabolism in the Tumor Microenvironment: Markers, Models, and Mechanisms. Annual Review of Pathology: Mechanisms of Disease, 2012, 7, 423-467.	22.4	249
133	Weight change associated with anastrozole and tamoxifen treatment in postmenopausal women with or at high risk of developing breast cancer. Breast Cancer Research and Treatment, 2012, 134, 727-734.	2.5	47
134	Effect of baseline serum vitamin D levels on aromatase inhibitors induced musculoskeletal symptoms: results from the IBIS-II, chemoprevention study using anastrozole. Breast Cancer Research and Treatment, 2012, 132, 625-629.	2.5	30
135	Lack of caveolin-1 (P132L) somatic mutations in breast cancer. Breast Cancer Research and Treatment, 2012, 132, 1185-1186.	2.5	7
136	Polymorphisms of CYP19A1 and response to aromatase inhibitors in metastatic breast cancer patients. Breast Cancer Research and Treatment, 2012, 133, 1191-1198.	2.5	36
137	Volumetric and Area-Based Breast Density Measurement in the Predicting Risk of Cancer at Screening (PROCAS) Study. Lecture Notes in Computer Science, 2012, , 228-235.	1.3	6
138	Mitochondrial Fission Induces Glycolytic Reprogramming in Cancer-Associated Myofibroblasts, Driving Stromal Lactate Production, and Early Tumor Growth. Oncotarget, 2012, 3, 798-810.	1.8	112
139	Prognostic Value of a Combined Estrogen Receptor, Progesterone Receptor, Ki-67, and Human Epidermal Growth Factor Receptor 2 Immunohistochemical Score and Comparison With the Genomic Health Recurrence Score in Early Breast Cancer. Journal of Clinical Oncology, 2011, 29, 4273-4278.	1.6	666
140	Cytokine production and inflammation drive autophagy in the tumor microenvironment. Cell Cycle, 2011, 10, 1784-1793.	2.6	137
141	Hydrogen peroxide fuels aging, inflammation, cancer metabolism and metastasis. Cell Cycle, 2011, 10, 2440-2449.	2.6	208
142	Anti-estrogen resistance in breast cancer is induced by the tumor microenvironment and can be overcome by inhibiting mitochondrial function in epithelial cancer cells. Cancer Biology and Therapy, 2011, 12, 924-938.	3.4	154
143	Migration and Inequality in Xinjiang: A Survey of Han and Uyghur Migrants in Urumqi. Eurasian Geography and Economics, 2011, 52, 119-139.	2.6	84
144	Stromalâ€“epithelial metabolic coupling in cancer: Integrating autophagy and metabolism in the tumor microenvironment. International Journal of Biochemistry and Cell Biology, 2011, 43, 1045-1051.	2.8	218

#	Article	IF	Citations
145	Preventive therapy for breast cancer: a consensus statement. Lancet Oncology, The, 2011, 12, 496-503.	10.7	196
146	10-year analysis of the ATAC trial: wrong conclusion? â€“ Authors' reply. Lancet Oncology, The, 2011, 12, 217.	10.7	2
147	Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Research, 2011, 13, 213.	5.0	153
148	Influence of Comorbidities and Age on Risk of Death Without Recurrence: A Retrospective Analysis of the Arimidex, Tamoxifen Alone or in Combination Trial. Journal of Clinical Oncology, 2011, 29, 4266-4272.	1.6	61
149	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. Growth and Change, 2011, 42, 200-226.	2.6	23
150	Fulvestrant Revisited: Efficacy and Safety of the 500-mg Dose. Clinical Breast Cancer, 2011, 11, 204-210.	2.4	38
151	Cancer cells metabolically "fertilize" the tumor microenvironment with hydrogen peroxide, driving the Warburg effect. Cell Cycle, 2011, 10, 2504-2520.	2.6	245
152	Comprehensive CYP2D6 genotype and adherence affect outcome in breast cancer patients treated with tamoxifen monotherapy. Breast Cancer Research and Treatment, 2011, 125, 279-287.	2.5	80
153	Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biology and Therapy, 2011, 12, 1101-1113.	3.4	99
154	Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ. Cell Cycle, 2011, 10, 4047-4064.	2.6	256
155	Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth. Cell Cycle, 2011, 10, 4065-4073.	2.6	110
156	Accelerated aging in the tumor microenvironment. Cell Cycle, 2011, 10, 2059-2063.	2.6	63
157	Ketones and lactate increase cancer cell â€œstemness,â€•driving recurrence, metastasis and poor clinical outcome in breast cancer. Cell Cycle, 2011, 10, 1271-1286.	2.6	295
158	Evidence for a stromal-epithelial â€œlactate shuttleâ€•in human tumors. Cell Cycle, 2011, 10, 1772-1783.	2.6	393
159	Understanding the metabolic basis of drug resistance. Cell Cycle, 2011, 10, 2521-2528.	2.6	97
160	Matrix remodeling stimulates stromal autophagy, â€œfuelingâ€•cancer cell mitochondrial metabolism and metastasis. Cell Cycle, 2011, 10, 2021-2034.	2.6	69
161	Defining bad stroma in human breast tumors. Cell Cycle, 2011, 10, 3056-3056.	2.6	1
162	Energy transfer in "parasitic" cancer metabolism. Cell Cycle, 2011, 10, 4208-4216.	2.6	144

#	Article	IF	Citations
163	Tamoxifen-Induced Reduction in Mammographic Density and Breast Cancer Risk Reduction: A Nested Case-Control Study. Journal of the National Cancer Institute, 2011, 103, 744-752.	6.3	358
164	Caveolin-1 and mitochondrial SOD2 (MnSOD) function as tumor suppressors in the stromal microenvironment. Cancer Biology and Therapy, 2011, 11, 383-394.	3.4	122
165	Glutamine fuels a vicious cycle of autophagy in the tumor stroma and oxidative mitochondrial metabolism in epithelial cancer cells. Cancer Biology and Therapy, 2011, 12, 1085-1097.	3.4	145
166	Can metabolomics in addition to genomics add to prognostic and predictive information in breast cancer?. BMC Medicine, 2010, 8, 73.	5.5	4
167	Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: Evidence for stromal-epithelial metabolic coupling. Cell Cycle, 2010, 9, 2412-2422.	2.6	130
168	Understanding the "lethal" drivers of tumor-stroma co-evolution. Cancer Biology and Therapy, 2010, 10, 537-542.	3.4	180
169	Prediction of Risk of Distant Recurrence Using the 21-Gene Recurrence Score in Node-Negative and Node-Positive Postmenopausal Patients With Breast Cancer Treated With Anastrozole or Tamoxifen: A TransATAC Study. Journal of Clinical Oncology, 2010, 28, 1829-1834.	1.6	647
170	Insights Into the Place of Fulvestrant for the Treatment of Advanced Endocrine Responsive Breast Cancer. Journal of Clinical Oncology, 2010, 28, 4548-4550.	1.6	13
171	Ketones and lactate â€œfuelâ€•tumor growth and metastasis. Cell Cycle, 2010, 9, 3506-3514.	2.6	526
172	HIF1-alpha functions as a tumor promoter in cancer-associated fibroblasts, and as a tumor suppressor in breast cancer cells. Cell Cycle, 2010, 9, 3534-3551.	2.6	207
173	Uptake of breast cancer prevention and screening trials. Journal of Medical Genetics, 2010, 47, 853-855.	3.2	16
174	Tumor cells induce the cancer associated fibroblast phenotype via caveolin-1 degradation: Implications for breast cancer and DCIS therapy with autophagy inhibitors. Cell Cycle, 2010, 9, 2423-2433.	2.6	238
175	The autophagic tumor stroma model of cancer or â€œbattery-operated tumor growthâ€• Cell Cycle, 2010, 9, 4297-4306.	2.6	165
176	Oxidative stress in cancer associated fibroblasts drives tumor-stroma co-evolution. Cell Cycle, 2010, 9, 3276-3296.	2.6	400
177	Effect of Body Mass Index on Recurrences in Tamoxifen and Anastrozole Treated Women: An Exploratory Analysis From the ATAC Trial. Journal of Clinical Oncology, 2010, 28, 3411-3415.	1.6	271
178	Breast cancer susceptibility variants alter risks in familial disease. Journal of Medical Genetics, 2010, 47, 126-131.	3.2	35
179	Autophagy in cancer associated fibroblasts promotes tumor cell survival. Cell Cycle, 2010, 9, 3515-3533.	2.6	377
180	Hormone Replacement Therapy and Breast Cancer. Recent Results in Cancer Research, 2010, 188, 115-124.	1.8	22

#	Article	IF	Citations
181	The autophagic tumor stroma model of cancer. Cell Cycle, 2010, 9, 3485-3505.	2.6	248
182	Lung cancer after treatment for breast cancer. Lancet Oncology, The, 2010, 11, 1184-1192.	10.7	30
183	Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncology, The, 2010, 11, 1135-1141.	10.7	1,017
184	The emerging breast cancer epidemic: early diagnosis and treatment. Breast Cancer Research, 2010, 12, S10.	5.0	21
185	Transcriptional evidence for the "Reverse Warburg Effect" in human breast cancer tumor stroma and metastasis: Similarities with oxidative stress, inflammation, Alzheimer's disease, and "Neuron-Glia Metabolic Coupling". Aging, 2010, 2, 185-199.	3.1	136
186	Endocrine Therapy. , 2010, , 329-352.		0
187	Uptake of Risk-Reducing Surgery in Unaffected Women at High Risk of Breast and Ovarian Cancer Is Risk, Age, and Time Dependent. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2318-2324.	2.5	132
188	Normal Breast Tissue Implanted into Athymic Nude Mice Identifies Biomarkers of the Effects of Human Pregnancy Levels of Estrogen. Cancer Prevention Research, 2009, 2, 257-264.	1.5	8
189	Biomarkers of Dietary Energy Restriction in Women at Increased Risk of Breast Cancer. Cancer Prevention Research, 2009, 2, 720-731.	1.5	41
190	A lower incidence of gynecologic adverse events and interventions with anastrozole than with tamoxifen in the ATAC trial. American Journal of Obstetrics and Gynecology, 2009, 200, 80.e1-80.e7.	1.3	19
191	Risk factors. Introduction to Session 1. Breast Cancer Research, 2009, 11, S2.	5.0	0
192	Breast tumour stroma is a prognostic indicator and target for therapy. Breast Cancer Research, 2009, 11, S16.	5.0	16
193	Overcoming endocrine resistance in breast cancerâ€"are signal transduction inhibitors the answer?. Breast Cancer Research and Treatment, 2008, 108, 307-317.	2.5	41
194	Penetrance estimates for BRCA1 and BRCA2based on genetic testing in a Clinical Cancer Genetics service setting: Risks of breast/ovarian cancer quoted should reflect the cancer burden in the family. BMC Cancer, 2008, 8, 155.	2.6	191
195	The endocrine prevention of breast cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2008, 22, 615-623.	4.7	38
196	Should lifestyle modifications be promoted to prevent breast cancer?. Breast Cancer Research, 2008, 10, S11.	5.0	2
197	Evaluation of the current knowledge limitations in breast cancer research: a gap analysis. Breast Cancer Research, 2008, 10, R26.	5.0	88
198	Guidance for the management of breast cancer treatment-induced bone loss: A consensus position statement from a UK Expert Group. Cancer Treatment Reviews, 2008, 34, S3-S18.	7.7	209

#	Article	IF	Citations
199	Effects of anastrozole on cognitive performance in postmenopausal women: a randomised, double-blind chemoprevention trial (IBIS II). Lancet Oncology, The, 2008, 9, 953-961.	10.7	108
200	Red clover isoflavones are safe and well tolerated in women with a family history of breast cancer. Menopause International, 2008, 14, 6-12.	1.6	61
201	Effect of Anastrozole on Bone Mineral Density: 5-Year Results From the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology, 2008, 26, 1051-1057.	1.6	363
202	Better Life Expectancy in Women with BRCA2 Compared with BRCA1 Mutations Is Attributable to Lower Frequency and Later Onset of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1535-1542.	2.5	15
203	Response and Resistance to the Endocrine Prevention of Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 201-211.	1.6	10
204	The Origin of Estrogen Receptor Î±-Positive and Î±-Negative Breast Cancer. Advances in Experimental Medicine and Biology, 2008, 617, 79-86.	1.6	1
205	Critical assessment of new risk factors for breast cancer: considerations for development of an improved risk prediction model. Endocrine-Related Cancer, 2007, 14, 169-187.	3.1	165
206	Long-Term Results of Tamoxifen Prophylaxis for Breast Cancer--96-Month Follow-up of the Randomized IBIS-I Trial. Journal of the National Cancer Institute, 2007, 99, 272-282.	6.3	510
207	The effects of sex steroid replacement therapy on an expanded panel of IGF-related peptides. Growth Hormone and IGF Research, 2007, 17, 210-219.	1.1	6
208	Breast cancer risk-assessment models. Breast Cancer Research, 2007, 9, 213.	5.0	142
209	Origins of breast cancer subtypes and therapeutic implications. Nature Clinical Practice Oncology, 2007, 4, 516-525.	4.3	155
210	Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. International Journal of Cancer, 2007, 121, 1017-1020.	5.1	86
211	Adult weight gain and central obesity in women with and without a family history of breast cancer: a case control study. Familial Cancer, 2007, 6, 287-294.	1.9	13
212	Does HER2 overexpression affect response to endocrine therapy in advanced cancer?. Nature Clinical Practice Oncology, 2006, 3, 78-79.	4.3	1
213	High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?. Breast Cancer Research, 2006, 8, 214.	5.0	28
214	BRCA1, BRCA2 and TP53 mutations in very early-onset breast cancer with associated risks to relatives. European Journal of Cancer, 2006, 42, 1143-1150.	2.8	139
215	The ‘Arimidex’, Tamoxifen, Alone or in Combination (ATAC) Trial: A Step Forward in the Treatment of Early Breast Cancer. Reviews on Recent Clinical Trials, 2006, 1, 207-215.	0.8	9
216	Predicting Compliance in a Breast Cancer Prevention Trial. Breast Journal, 2006, 12, 446-450.	1.0	20

#	Article	IF	Citations
217	Fulvestrant (â€˜Faslodexâ€™): Current and future role in breast cancer management. Critical Reviews in Oncology/Hematology, 2006, 57, 265-273.	4.4	51
218	Quality of Life of Postmenopausal Women in the ATAC (â€œArimidexâ€, Tamoxifen, Alone or in) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 7 Cancer Research and Treatment, 2006, 100, 273-284.	2.5	218
219	Late Toxicity Is Not Increased in BRCA1/BRCA2 Mutation Carriers Undergoing Breast Radiotherapy in the United Kingdom. Clinical Cancer Research, 2006, 12, 7025-7032.	7.0	75
220	Re: Tamoxifen for the Prevention of Breast Cancer: Current Status of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute, 2006, 98, 643-643.	6.3	9
221	Acute Chemotherapyâ€“Related Toxicity Is Not Increased in BRCA1 and BRCA2 Mutation Carriers Treated for Breast Cancer in the United Kingdom. Clinical Cancer Research, 2006, 12, 7033-7038.	7.0	36
222	Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocrine-Related Cancer, 2006, 13, 689-706.	3.1	100
223	Insulin-like growth factor (IGF)-I, IGF binding protein-3, and breast cancer risk: eight years on. Endocrine-Related Cancer, 2006, 13, 273-278.	3.1	115
224	Selective oestrogen receptor modulators, aromatase inhibitors and the female breast. Current Opinion in Obstetrics and Gynecology, 2005, 17, 429-434.	2.0	1
225	Defining the Roles of Aromatase Inhibitors in the Adjuvant Treatment of Early-Stage Breast Cancer. Clinical Breast Cancer, 2005, 6, 302-309.	2.4	11
226	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma. Cancer, 2005, 104, 236-239.	4.1	154
227	Phase III Trial of Epirubicin Plus Paclitaxel Compared With Epirubicin Plus Cyclophosphamide As First-Line Chemotherapy for Metastatic Breast Cancer: United Kingdom National Cancer Research Institute Trial AB01. Journal of Clinical Oncology, 2005, 23, 8322-8330.	1.6	57
228	Association of Gain and Loss of Weight before and after Menopause with Risk of Postmenopausal Breast Cancer in the Iowa Women's Health Study. Cancer Epidemiology Biomarkers and Prevention, 2005, 14, 656-661.	2.5	376
229	Overview of the impact of conventional systemic therapies on breast cancer. Endocrine-Related Cancer, 2005, 12, S9-S16.	3.1	15
230	Preventing cancer, cardiovascular disease, and diabetes. Lancet, The, 2005, 365, 1449-1451.	13.7	36
231	Adjuvant aromatase inhibitors for breast cancer. Lancet, The, 2005, 366, 431-433.	13.7	31
232	The Group Room. Lancet Oncology, The, 2005, 6, 268.	10.7	0
233	Lung cancer after treatment for Hodgkin's lymphoma: a systematic review. Lancet Oncology, The, 2005, 6, 773-779.	10.7	103
234	Are aromatase inhibitors superior to antiestrogens?. Journal of Steroid Biochemistry and Molecular Biology, 2005, 93, 237-247.	2.5	33

#	Article	IF	Citations
235	Vascular effects of aromatase inhibitors: Data from clinical trials. Journal of Steroid Biochemistry and Molecular Biology, 2005, 95, 143-149.	2.5	42
236	The future of fulvestrant (â€˜Faslodexâ€™). Cancer Treatment Reviews, 2005, 31, S26-S33.	7.7	22
237	Clinical development of fulvestrant (â€˜Faslodexâ€™). Cancer Treatment Reviews, 2005, 31, S3-S9.	7.7	23
238	A putative human breast stem cell population is enriched for steroid receptor-positive cells. Developmental Biology, 2005, 277, 443-456.	2.0	312
239	New developments in the treatment of postmenopausal breast cancer. Trends in Endocrinology and Metabolism, 2005, 16, 420-428.	7.1	21
240	Mechanisms of Disease: prediction and prevention of breast cancerâ€”cellular and molecular interactions. Nature Clinical Practice Oncology, 2005, 2, 635-646.	4.3	29
241	Adjuvant Docetaxel for Node-Positive Breast Cancer. New England Journal of Medicine, 2005, 352, 2302-2313.	27.0	892
242	Early stopping of clinical trials. Breast Cancer Research, 2005, 7, 181-3.	5.0	7
243	Morrow M, Jordan VC: Managing Breast Cancer Risk. 1st Edition. Hamilton, Ontario: BC Decker Inc. Breast Cancer Research, 2005, 7, 1.	5.0	0
244	Comparison of Fulvestrant Versus Tamoxifen for the Treatment of Advanced Breast Cancer in Postmenopausal Women Previously Untreated With Endocrine Therapy: A Multinational, Double-Blind, Randomized Trial. Journal of Clinical Oncology, 2004, 22, 1605-1613.	1.6	392
245	Quality of Life of Postmenopausal Women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. Journal of Clinical Oncology, 2004, 22, 4261-4271.	1.6	283
246	Does hormone therapy for the treatment of breast cancer have a detrimental effect on memory and cognition? A pilot study. Psycho-Oncology, 2004, 13, 61-66.	2.3	195
247	The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Practice and Research in Clinical Endocrinology and Metabolism, 2004, 18, 47-66.	4.7	124
248	Strategies for Managing Breast Cancer Risk After the Menopause. Treatments in Endocrinology: Guiding Your Management of Endocrine Disorders, 2004, 3, 289-307.	1.8	3
249	Endocrinology and hormone therapy in breast cancer: Aromatase inhibitors versus antioestrogens. Breast Cancer Research, 2004, 6, 269-74.	5.0	49
250	An early peak of relapse after surgery for breast cancer. Breast Cancer Research, 2004, 6, 255-7.	5.0	5
251	Steroid receptors in human breast cancer. Trends in Endocrinology and Metabolism, 2004, 15, 316-323.	7.1	73
252	Spreading the word, but not too thinly. Lancet, The, 2004, 363, 165-166.	13.7	0

#	Article	IF	Citations
253	Adjuvant Use of Anastrozole in Breast Cancer. Journal of Clinical Oncology, 2004, 22, 1524-1526.	1.6	6
254	Fulvestrant versus anastrozole for the treatment of advanced breast carcinoma in postmenopausal women. Cancer, 2003, 98, 229-238.	4.1	305
255	Longâ€term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma. Cancer, 2003, 98, 1735-1744.	4.1	836
256	Pharmacokinetic, biochemical and clinical effects of dimethyltriazenoimidazole-4-carboxamide-bischloroethylnitrosourea combination therapy in patients with advanced breast cancer. International Journal of Cancer, 2003, 103, 686-692.	5.1	5
257	A Roundtable Discussion of Aromatase Inhibitors as Therapy for Breast Cancer. Breast Journal, 2003, 9, 213-222.	1.0	7
258	Bayesian evaluation of breast cancer screening using data from two studies. Statistics in Medicine, 2003, 22, 1661-1674.	1.6	8
259	Are BRCA1- and BRCA2-related breast cancers associated with increased mortality?. Breast Cancer Research, 2003, 6, E7.	5.0	19
260	International Expert Panel on the Use of Primary (Preoperative) Systemic Treatment of Operable Breast Cancer: Review and Recommendations. Journal of Clinical Oncology, 2003, 21, 2600-2608.	1.6	322
261	Do Women Understand the Odds? Risk Perceptions and Recall of Risk Information in Women with a Family History of Breast Cancer. Public Health Genomics, 2003, 6, 214-223.	1.0	34
262	Fulvestrant (Faslodexâ„¢): current status in the therapy of breast cancer. Expert Review of Anticancer Therapy, 2002, 2, 151-160.	2.4	31
263	Survival in prospectively ascertained familial breast cancer: Analysis of a series stratified by tumour characteristics,BRCAmutations and oophorectomy. International Journal of Cancer, 2002, 101, 555-559.	5.1	99
264	Breast cancer: Aromatase inhibitors take on tamoxifen. Nature Medicine, 2002, 8, 1341-1344.	30.7	30
265	Where do selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) now fit into breast cancer treatment algorithms?. Journal of Steroid Biochemistry and Molecular Biology, 2001, 79, 227-237.	2.5	27
266	Tamoxifen for the Prevention of Breast Cancer: Psychosocial Impact on Women Participating in Two Randomized Controlled Trials. Journal of Clinical Oncology, 2001, 19, 1885-1892.	1.6	214
267	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. Breast Cancer Research and Treatment, 2001, 67, 111-116.	2.5	219
268	Clarification of Anastrozole/Megestrol Acetate Trial Program Design. Journal of Clinical Oncology, 2000, 18, 4109-4109.	1.6	0
269	Tamoxifen versus the newer SERMs: what is the evidence?. Annals of Oncology, 2000, 11, 255-266.	1.2	3
270	Serum Soluble Vascular Cell Adhesion Molecule-1: Role as a Surrogate Marker of Angiogenesis. Journal of the National Cancer Institute, 2000, 92, 1329-1336.	6.3	114

#	Article	IF	Citations
271	Title is missing!. Annals of Oncology, 2000, 11, 255-266.	1.2	4
272	The therapeutic potential of novel aromatase inhibitors in breast cancer. Expert Opinion on Investigational Drugs, 1999, 8, 269-279.	4.1	4
273	Estrogen responsiveness and control of normal human breast proliferation. Journal of Mammary Gland Biology and Neoplasia, 1998, 3, 23-35.	2.7	157
274	Effect of early American results on patients in a tamoxifen prevention trial (IBIS). Lancet, The, 1998, 352, 1222.	13.7	11
275	Estrogen sensitivity of normal human breast tissue in vivo and implanted into athymic nude mice: Analysis of the relationship between estrogen-induced proliferation and progesterone receptor expression. Breast Cancer Research and Treatment, 1997, 45, 121-133.	2.5	235
276	Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes. Breast Cancer Research and Treatment, 1996, 41, 31-41.	2.5	42
277	Allelic imbalance on chromosome I in human breast cancer. II. Microsatellite repeat analysis. Genes Chromosomes and Cancer, 1995, 12, 24-31.	2.8	51
278	â€˜Should I Take HRT, Doctor?â€™ Hormone Replacement Therapy in Women at Increased Risk of Breast Cancer and in Survivors of the Disease. The Journal of the British Menopause Society, 1995, 1, 9-17.	1.3	3
279	Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer. Lancet, The, 1995, 345, 989-990.	13.7	28
280	Phenotypic heterogeneity in breast fibroblasts: Functional anomaly in fibroblasts from histologically normal tissue adjacent to carcinoma. International Journal of Cancer, 1994, 59, 25-32.	5.1	46
281	Reduction in apoptosis relative to mitosis in histologically normal epithelium accompanies fibrocystic change and carcinoma of the premenopausal human breast. Journal of Pathology, 1992, 167, 25-32.	4.5	120
282	Viridans streptococcal bacteraemia in patients with haematological and solid malignancies. European Journal of Cancer & Clinical Oncology, 1991, 27, 409-411.	0.7	49
283	Oral contraceptive (OCP) use increases proliferation and decreases oestrogen receptor content of epithelial cells in the normal human breast. International Journal of Cancer, 1991, 48, 206-210.	5.1	117
284	Tenascin distribution in the normal human breast is altered during the menstrual cycle and in carcinoma. Differentiation, 1990, 42, 199-207.	1.9	62
285	Comparative pharmacokinetics of escalating doses of doxorubicin in patients with metastatic breast cancer. Cancer Chemotherapy and Pharmacology, 1990, 25, 435-439.	2.3	20
286	4 New endocrine approaches to breast cancer. Bailliere's Clinical Endocrinology and Metabolism, 1990, 4, 67-84.	1.0	6
287	The Relationship between Age and the Effect of Adjuvant Therapies in Women with Primary Breast Cancer. Hormone Research, 1989, 32, 231-237.	1.8	1
288	A phase II trial of oral idarubicin plus dibromodulcitol in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1989, 25, 141-143.	0.7	11

#	Article	IF	Citations
289	Serum bioactive lactogenic hormone levels in women with familial breast cancer and their relatives. European Journal of Cancer & Clinical Oncology, 1989, 25, 1719-1725.	0.7	10
290	A phase II study of oral weekly 4-demethoxydaunorubicin in advanced breast cancer. European Journal of Cancer & Clinical Oncology, 1987, 23, 391-394.	0.7	15
291	Infiltrating lobular carcinoma of the breast: Response to endocrine therapy and survival. European Journal of Cancer & Clinical Oncology, 1987, 23, 979-982.	0.7	33
292	Clinical pharmacology of oral and intravenous 4-demethoxydaunorubicin. Cancer Chemotherapy and Pharmacology, 1987, 19, 138-42.	2.3	39
293	Assessment of renal function during high-dose cis-platinum therapy in patients with ovarian carcinoma. Cancer Chemotherapy and Pharmacology, 1982, 8, 281-4.	2.3	27
294	Pharmacokinetics of oral and intravenous fluorouracil in humans. Journal of Pharmaceutical Sciences, 1980, 69, 1428-1431.	3.3	44
295	Labor Market Segmentation in Urumqi, Xinjiang: Exposing Labor Market Segments and Testing the Relationship between Migration and Segmentation. SSRN Electronic Journal, 0, , .	0.4	2
296	Technological relatedness and asymmetrical firm productivity gains under market reforms in China. Cambridge Journal of Regions, Economy and Society, 0, , rsw024.	3.0	11
297	Clustering Effects on Firm Exporting with Productivity-Enhancing R&D in China. SSRN Electronic Journal, 0, , .	0.4	1
298	Innovation and Firm Performance in the People's Republic of China: A Structural Approach with Spillovers. SSRN Electronic Journal, 0, , .	0.4	6
299	Urban Agglomeration, Selection and the Impact of Policy Distortions on Firm Productivity in China. SSRN Electronic Journal, 0, , .	0.4	3
300	A Structural Model of Indigenous Innovation and Catch-Up for Developing Economies. SSRN Electronic Journal, 0, , .	0.4	1
301	Minimum Wage Impacts on Inequality, Job Formality and the Ethnic Wage Gap in Urban China. SSRN Electronic Journal, 0, , .	0.4	2
302	Ethnicity, Start-Up Finance, and Entrepreneurship in China. SSRN Electronic Journal, 0, , .	0.4	1
303	Direct and Spillover Effects of Targeted Cash Transfers on Ethnic Rural-Urban Migration in China. SSRN Electronic Journal, 0, , .	0.4	1
304	Inter-Industry Relatedness, Absorptive Capacity and Firm Productivity in a Transitioning Chinese Economy. SSRN Electronic Journal, 0, , .	0.4	3
305	Picking Winnerss in China: Do Subsidies Matter for Indigenous Innovation and Firm Productivity?. SSRN Electronic Journal, 0, , .	0.4	1
306	Minimum Wages, Spillovers and the Unconditional Wage Distribution in Urban China: Do Ethnic Minorities Benefit?. SSRN Electronic Journal, 0, , .	0.4	0

#	Article	IF	Citations
307	Heterogenous Impacts of China's Economic and Development Zone Program. SSRN Electronic Journal, 0, , .	0.4	0